After-hours movers: Zscaler, Honeywell, Microchip Technology and more
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- FedEx falls 4% as FY2027 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Janux Therapeutics (JANX) PT Raised to $115 at Stifel
December 3, 2024 8:22 AM ESTStifel analyst Bradley Canino raised the price target on Janux Therapeutics (NASDAQ: JANX) to $115.00 (from $70.00) while maintaining a Buy rating.
The analyst comments "The JANX007 (PSMA-TRACTr) phase 1 update (LINK) leads us to increase our PoS for 2L and 3L mCRPC to 50% and 65%, respectively... More
William Blair on Janux Therapeutics (JANX): 'Exceeding Investor Expectations and Raising the Bar in mCRPC'
December 3, 2024 7:06 AM ESTWilliam Blair analyst Matt Phipps reiterated an Outperform rating on Janux Therapeutics (NASDAQ: JANX).
The analyst comments "On Monday, December 2, Janux disclosed updated clinical results with JANX007, the companys PSMAxCD3 TRACTr bispecific T-cell engager, in patients with heavily pretreated metastatic castrate resistant prostate cancer (mCRPC), demonstrating... More
Zscaler (ZS) PT Raised to $235 at Citi
December 3, 2024 7:03 AM ESTCiti analyst Fatima Boolani raised the price target on Zscaler (NASDAQ: ZS) to $235.00 (from $230.00) while maintaining a Buy rating.
The analyst comments "FY25 billings and rev guidance is raised ~0.6pt/~1pt at the midpoint, largely reflecting the F1Q25 beat. Here, F2Q25E billings guide (implied $719M, up ~15% YoY, at the midpoint) is largely unchanged as the company now... More
Janux Therapeutics (JANX) PT Raised to $91 at Leerink Partners
December 3, 2024 6:55 AM ESTLeerink Partners analyst Jeffrey La Rosa raised the price target on Janux Therapeutics (NASDAQ: JANX) to $91.00 (from $79.00) while maintaining a Outperform rating.
The analyst comments "Bottom Line: Janux (JANX, OP) delivered with updated Ph 1 dose escalation data for lead candidate JANX007 (masked PSMA x... More
Credo Technology Group Holding Ltd. (CRDO) PT Raised to $70 at Needham
December 3, 2024 6:37 AM ESTNeedham analyst N. Quinn Bolton raised the price target on Credo Technology Group Holding Ltd. (NASDAQ: CRDO) to $70.00 (from $43.00) while maintaining a Buy rating.
The analyst comments "Credo reported a strong beat and guided revenue $35MM (41%) above our estimate as customer forecasts and... More
Microchip Technology (MCHP) PT Lowered to $87 at Stifel
December 3, 2024 6:36 AM ESTStifel analyst Tore Svanberg lowered the price target on Microchip Technology (NASDAQ: MCHP) to $87.00 (from $90.00) while maintaining a Buy rating.
The analyst comments " After the market close on December 2, 2024, MCHP updated its outlook for F3Q25E (Dec), with revenue... More
Credo Technology Group Holding Ltd. (CRDO) PT Raised to $75 at Stifel
December 3, 2024 6:21 AM ESTStifel analyst Tore Svanberg raised the price target on Credo Technology Group Holding Ltd. (NASDAQ: CRDO) to $75.00 (from $50.00) while maintaining a Buy rating.
The analyst comments "Strong Oct Q beat. Revenue of $72.0mn (+20.6% q/q) was +8.3% vs. our estimate (and above the high-end of... More
Stifel Reiterates Buy Rating on Janux Therapeutics (JANX)
December 3, 2024 5:27 AM ESTStifel analyst Bradley Canino reiterated a Buy rating and $70.00 price target on Janux Therapeutics (NASDAQ: JANX).
The analyst comments "Updated ph.1a JANX007 (PSMA-TRACTr) ~5L mCRPC data at therapeutic weekly dose regimens suggest a potentially guaranteed biochemical PSA response pre-Pluvicto, with three-quarters lasting >12wks.... More
Janux Therapeutics (JANX) PT Raised to $100 at BTIG, 'The World Is Not Enough — 007 Strikes Again Exceeding The Street's Highest Expectations'
December 3, 2024 5:26 AM ESTBTIG analyst Justin Zelin raised the price target on Janux Therapeutics (NASDAQ: JANX) to $100.00 (from $82.00) while maintaining a Buy rating.
The analyst comments "Janux surpassed the street's high expectations with their eagerly anticipated data update today (see our preview note here). Heading into the data, we've heard investor concerns that expectations were too high for JANX to meet our bull case scenario of >60% PSA50 at 12-wks,... More
Evercore ISI Reiterates Outperform Rating on Zscaler (ZS)
December 3, 2024 5:19 AM ESTEvercore ISI analyst Peter Levine reiterated an Outperform rating and $245.00 price target on Zscaler (NASDAQ: ZS).
The analyst comments "F1Q was well-executed, with most metrics meeting expectations. The after-hours sell-off was driven by the tepid guide and news that the CFO will be retiring. While this quarter's results do not change our thesis, they raise concerns about why the GTM shift, now passing the 1yr mark, is taking longer than anticipated, which is why investors are questioning the feasibility of the expected 2H ramp. From mgmts perspective, the mechanisms driving the 2H... More
Citi Reiterates Buy Rating on Honeywell International (HON)
December 3, 2024 5:06 AM ESTCiti analyst Andrew Kaplowitz reiterated a Buy rating and $244.00 price target on Honeywell International (NASDAQ: HON)
The analyst comments "We view HONs announced strategic agreement with Bombardier to collaborate and for HON to provide advanced avionics, propulsion and satellite communications technologies for... More
BofA Securities Upgrades Credo Technology Group Holding Ltd. (CRDO) to Buy
December 3, 2024 4:59 AM ESTBofA Securities analyst Vivek Arya upgraded Credo Technology Group Holding Ltd. (NASDAQ: CRDO) from Underperform to Buy with a price target of $80.00 (from $27.00).
The analyst comments "Following a solid beat and material raise earnings call, we double upgrade CRDO to Buy from Underperform, raise FY26/27E EPS by 65%/88% to $1.01/$1.51, and take our PO... More
